Loading...

Cannex Capital Holdings

OTCPK:CNXX.F
Snowflake Description

Excellent balance sheet with concerning outlook.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CNXX.F
OTCPK
CA$208M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Cannex Capital Holdings Inc., through its subsidiaries, leases real estate properties and sells supplies to cannabis cultivators, processors, and dispensaries in the United States and Canada. The last earnings update was 178 days ago. More info.


Add to Portfolio Compare Print
  • Cannex Capital Holdings has significant price volatility in the past 3 months.
CNXX.F Share Price and Events
7 Day Returns
-7.6%
OTCPK:CNXX.F
1.2%
US Pharmaceuticals
1.4%
US Market
1 Year Returns
-
OTCPK:CNXX.F
9.7%
US Pharmaceuticals
2.3%
US Market
CNXX.F Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cannex Capital Holdings (CNXX.F) -7.6% 28.8% 0.4% - - -
US Pharmaceuticals 1.2% 3% -1.4% 9.7% 13.9% 17.8%
US Market 1.4% 5.6% 5.7% 2.3% 44.2% 40.9%
1 Year Return vs Industry and Market
  • No trading data on CNXX.F.
  • No trading data on CNXX.F.
Price Volatility
Industry
5yr Volatility vs Market

CNXX.F Value

 Is Cannex Capital Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Cannex Capital Holdings. This is due to cash flow or dividend data being unavailable. The share price is $0.819.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cannex Capital Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cannex Capital Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:CNXX.F PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-04-30) in USD $-0.05
CNSX:CNNX Share Price ** CNSX (2019-02-21) in CAD CA$1.07
CNSX:CNNX Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.758 $0.81
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 29 Publicly-Listed Pharmaceuticals Companies 16.92x
United States of America Market PE Ratio Median Figure of 3,045 Publicly-Listed Companies 17.39x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cannex Capital Holdings.

OTCPK:CNXX.F PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:CNNX Share Price ÷ EPS (both in USD)

= 0.81 ÷ -0.05

-16.48x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cannex Capital Holdings is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Cannex Capital Holdings is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Cannex Capital Holdings's expected growth come at a high price?
Raw Data
OTCPK:CNXX.F PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -16.48x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 23 Publicly-Listed Pharmaceuticals Companies 1.62x
United States of America Market PEG Ratio Median Figure of 2,118 Publicly-Listed Companies 1.44x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cannex Capital Holdings, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cannex Capital Holdings's assets?
Raw Data
OTCPK:CNXX.F PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-04-30) in USD $0.17
CNSX:CNNX Share Price * CNSX (2019-02-21) in CAD CA$1.07
CNSX:CNNX Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.758 $0.81
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 179 Publicly-Listed Pharmaceuticals Companies 2.97x
United States of America Market PB Ratio Median Figure of 5,129 Publicly-Listed Companies 1.87x
OTCPK:CNXX.F PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:CNNX Share Price ÷ Book Value per Share (both in USD)

= 0.81 ÷ 0.17

4.8x

* Primary Listing of Cannex Capital Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cannex Capital Holdings is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Cannex Capital Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Cannex Capital Holdings has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CNXX.F Future Performance

 How is Cannex Capital Holdings expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
17.6%
Expected annual growth in revenue.
Earnings growth vs Low Risk Savings
Is Cannex Capital Holdings expected to grow at an attractive rate?
  • Unable to compare Cannex Capital Holdings's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Cannex Capital Holdings's earnings growth to the United States of America market average as no estimate data is available.
  • Cannex Capital Holdings's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
OTCPK:CNXX.F Future Growth Rates Data Sources
Data Point Source Value (per year)
OTCPK:CNXX.F Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 17.6%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 19.8%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.7%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:CNXX.F Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:CNXX.F Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-04-30 17 1
2019-04-30 15 1
OTCPK:CNXX.F Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-04-30 12 4 -6
2017-09-30 6 3 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Cannex Capital Holdings is high growth as no earnings estimate data is available.
  • Cannex Capital Holdings's revenue is expected to grow by 17.6% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:CNXX.F Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Cannex Capital Holdings Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:CNXX.F Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-04-30
2019-04-30
OTCPK:CNXX.F Past Financials Data
Date (Data in USD Millions) EPS *
2018-04-30 -0.05
2017-09-30 -0.16

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Cannex Capital Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Cannex Capital Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cannex Capital Holdings has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CNXX.F Past Performance

  How has Cannex Capital Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cannex Capital Holdings's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Cannex Capital Holdings does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Cannex Capital Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Cannex Capital Holdings's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Cannex Capital Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cannex Capital Holdings Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:CNXX.F Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-04-30 11.90 -6.34 8.85
2017-09-30 5.72 -2.09 0.63

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Cannex Capital Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Cannex Capital Holdings has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Cannex Capital Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Cannex Capital Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cannex Capital Holdings has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CNXX.F Health

 How is Cannex Capital Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cannex Capital Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cannex Capital Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Cannex Capital Holdings's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cannex Capital Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cannex Capital Holdings Company Filings, last reported 9 months ago.

OTCPK:CNXX.F Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-04-30 31.03 7.43 11.86
2017-09-30 1.26 25.72 0.28
  • Cannex Capital Holdings's level of debt (23.9%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Cannex Capital Holdings's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making Cannex Capital Holdings has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making Cannex Capital Holdings has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -1.9% per year.
X
Financial health checks
We assess Cannex Capital Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cannex Capital Holdings has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CNXX.F Dividends

 What is Cannex Capital Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Cannex Capital Holdings dividends.
If you bought $2,000 of Cannex Capital Holdings shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Cannex Capital Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Cannex Capital Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:CNXX.F Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.7%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2001 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:CNXX.F Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2020-04-30
2019-04-30

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Cannex Capital Holdings has not reported any payouts.
  • Unable to verify if Cannex Capital Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Cannex Capital Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Cannex Capital Holdings has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Cannex Capital Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cannex Capital Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cannex Capital Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CNXX.F Management

 What is the CEO of Cannex Capital Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Anthony John Dutton
COMPENSATION $60,000
AGE 61
TENURE AS CEO 0.9 years
CEO Bio

Mr. Anthony John Guy Dutton is a Principal of Delu Corp. Mr. Dutton serves as the Chief Executive Officer of DELU Enterprises Ltd. He has been President at Arco Resources Corp. since January 2016 and served as Chief Executive Officer January 2016. Mr. Dutton served as a Vice President of Corporate Relations Special Projects at IBC Advanced Alloys Corp. from April 07, 2016 to October 31, 2016. He served as the Chief Executive Officer of IBC Advanced Alloys Corp. (formerly, International Beryllium Corporation) since May 2006 until April 07, 2016 and served as its President from September 15, 2007 to April 07, 2016. Since 2006, Mr. Dutton has been a Principal of Primary Capital Group, where he advises small to medium sized companies on corporate finance issues including working capital allocation and the management of a its funding requirements via the public and private capital markets. He serves as a Director of Business Development at Imara Energy Corp. Mr. Dutton is a seasoned business executive and entrepreneur with a successful track record as an early stage investor and business founder. He served as the President of IBC Advanced Alloys Corp. since May 2006 until July 17, 2007 and also served as its Secretary. Mr. Dutton served as the Chief Executive Officer, President and Chief Financial Officer of Green Park Capital Corp., since June 4, 2007 and its Secretary since June 13, 2007. His areas of expertise are corporate finance, business development and strategic management. He is regularly engaged in developing strategic and financial plans for early stage and high growth companies. Since 2006, he served as the Chief Executive Officer, Chief Financial Officer, President and Secretary of Janina Resources Limited. He served as Secretary at IBC Advanced Alloys Corp. From 2000 to 2003, he served as Director of Corporate Communications of XML Global Technologies Inc. From 2004 to 2006, he served as a Corporate Finance and Strategic Advisor for Curzon Capital Inc. Mr. Dutton has been a Director of Josephine Mining Corp., since June 4, 2007. He has been a Director of Arco Resources Corp., since December 20, 2011. He has been an Independent Director of Trakopolis IoT Corp. since October 28, 2016. He serves as an Independent Director of JPY Holdings Ltd. He has been Director of 0903658 B.C. Ltd. (formerly Centric Energy Corp.) since September 25, 2009. He serves as Director of Imara Energy Corp. He served as a Director at IBC Advanced Alloys Corp. from May 12, 2006 to October 31, 2016. He served as a Director at War Eagle Mining Co. Inc., from March 20, 2009 to November 7, 2012. He served as a Director of Green Park Capital Corp. since June 4, 2007. He served as a Director of Janina Resources Ltd., From 2003 to 2004, he was a self-employed Strategic Business Consultant. Mr. Dutton holds a BA in Economics from the University of British Columbia, a Masters of Architecture from Dalhousie University and a Joint MBA from the Cranfield School of Management in the United Kingdom and Groupe ESC in Lyon, France.

CEO Compensation
  • Anthony John's compensation has increased whilst company is loss making.
  • Anthony John's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure of the Cannex Capital Holdings management team in years:

0.6
Average Tenure
  • The average tenure for the Cannex Capital Holdings management team is less than 2 years, this suggests a new team.
Management Team

Anthony John Dutton

TITLE
CEO, President & Director
COMPENSATION
$60K
AGE
61
TENURE
0.9 yrs

Leo Gontmakher

TITLE
COO & Director
COMPENSATION
$656K
TENURE
0.9 yrs

Greg Marshall

TITLE
COMPENSATION
$519K
TENURE
0.3 yrs

David Croom

TITLE
Chief Financial Officer
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure of the Cannex Capital Holdings board of directors in years:

0.9
Average Tenure
  • The average tenure for the Cannex Capital Holdings board of directors is less than 3 years, this suggests a new board.
Board of Directors

Roman Tkachenko

TITLE
Chairman
COMPENSATION
$3K
TENURE
0.8 yrs

Anthony John Dutton

TITLE
CEO, President & Director
COMPENSATION
$60K
AGE
61
TENURE
0.9 yrs

Leo Gontmakher

TITLE
COO & Director
COMPENSATION
$656K
TENURE
0.9 yrs

Dmitriy Goykhman

TITLE
Independent Director
COMPENSATION
$8K
TENURE
0.9 yrs

Tom Peters

TITLE
Independent Director
COMPENSATION
$19K
TENURE
0.9 yrs

Ian Smith

TITLE
Member of Capital Markets Advisory
TENURE
0.8 yrs

Jerry Derevyanny

TITLE
Non-Independent Director
TENURE
0.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Cannex Capital Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cannex Capital Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CNXX.F News

Simply Wall St News

CNXX.F Company Info

Map
Description

Cannex Capital Holdings Inc., through its subsidiaries, leases real estate properties and sells supplies to cannabis cultivators, processors, and dispensaries in the United States and Canada. It is involved in the provision of turn-key real estate with operational infrastructure; cannabis growing-related consulting services; purchasing agent services; and sale of packaging and other non-cannabis product inputs, such as soil, indoor lighting, and packaging. The company is headquartered in Vancouver, Canada.

Details
Name: Cannex Capital Holdings Inc.
CNXX.F
Exchange: OTCPK
Founded:
CA$157,364,444
183,713,937
Website: http://www.cannexcapital.com
Address: Cannex Capital Holdings Inc.
1241 Alberni Street,
Vancouver,
British Columbia, V6E 4R4,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX CNNX Common Shares Canadian National Stock Exchange CA CAD 14. Mar 2018
OTCPK CNXX.F Common Shares Pink Sheets LLC US USD 14. Mar 2018
Number of employees
Current staff
Staff numbers
0
Cannex Capital Holdings employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/02/22 01:19
End of day share price update: 2019/02/21 00:00
Last estimates confirmation: 2018/11/23
Last earnings filing: 2018/08/28
Last earnings reported: 2018/04/30
Last annual earnings reported: 2018/04/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.